Prenatal Tests
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pre-Term Pre-Labour Rupture of Membranes and the Role of Amniocentesis
Fetal and Maternal Medicine Review 2010; 21:2 75–88 C Cambridge University Press 2010 doi:10.1017/S096553951000001X First published online 15 March 2010 PRE-TERM PRE-LABOUR RUPTURE OF MEMBRANES AND THE ROLE OF AMNIOCENTESIS 1,2 ANNA P KENYON, 1,2 KHALIL N ABI-NADER AND 2 PRANAV P PANDYA 1Elizabeth Garrett Anderson Institute for Women’s Health, University College London, 86-96 Chenies Mews, London WCIE 6NX. 2Fetal Medicine Unit, University College London Hospitals NHS Foundation Trust, 235 Euston Rd, London NWI 2BU. INTRODUCTION Pre-labour premature rupture of membranes (PPROM) is defined as rupture of membranes more than 1 hour prior to the onset of labour at <37 weeks gestation. PPROM occurs in approximately 3% of pregnancies and is responsible for a third of all preterm births.1 Once membranes are ruptured prolonging the pregnancy has no maternal physical advantage but fetal morbidity and mortality are improved daily at early gestations: 19% of those infants born <25 weeks develop cerebral palsy (CP) and 28% have severe motor disability.2 Those infants born extremely pre term (<28 weeks) cost the public sector £75835 (95% CI £27906–145508) per live birth3 not to mention the emotional cost to the family. To prolong gestation is therefore the suggested goal: however how and why might we delay birth in those at risk? PPROM is one scenario associated with preterm birth and here we discuss the causative mechanisms, sequelae, latency, strategies to prolong gestation (antibiotics) and consider the role of amniocentesis. We will also discuss novel therapies. PATHOPHYSIOLOGY OF MEMBRANE RUPTURE The membranes, which act to protect and isolate the fetus, are composed of two layers. -
Prenatal Testing Options
PRENATAL TESTING OPTIONS There are many types of tests available during pregnancy. No test can detect every possible condition, however there are many tests that can provide more information. Patients may elect or decline any of these tests as they are all optional. NT Ultrasound Detailed Ultrasound SCREENING CA PNS 1st Blood Draw CA PNS 2nd Blood Draw Cell-Free DNA Screening pregnancy week 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 DIAGNOSTIC CVS Amniocentesis SCREENING TESTS Screening tests provide probabilities (odds) of having a baby with certain conditions, however screening tests cannot detect all cases of these conditions. Screening tests are performed through maternal blood and ultrasound, so there is no risk for miscarriage from these tests. Patients will receive either “screen negative” or “screen positive” results from their screening tests. When results are screen negative, these are considered low-risk for that condition, however it is not impossible that the baby has that condition. When results are screen positive, these are considered high-risk for that condition, however most women with screen positive results are carrying a healthy baby! Follow up testing is available to confirm screening results. California Prenatal Screening Program (CA PNS) (also called Sequential Integrated Screening) Combines blood draw(s) and the NT ultrasound with maternal age risk to screen for Down syndrome, trisomy 18, open neural tube defects (example: spina bifida), and Smith-Lemli-Opitz syndrome In a pregnant woman’s blood there are natural -
Chorionic Villus Sample CVS Brochure
CVS C Chorionic Villus Sampling G A A T GENETICS LABORATORIES GENETICS LABORATORIES GENETICS LABORATORIES 3/2015 ou are being asked to consider prena- tal diagnosis in your current pregnancy. Y Chorionic villus sampling (CVS) is available as a method of prenatal testing for women who are less than 13 weeks pregnant. This test can be performed earlier than amniocentesis, which is usually performed between 15 and 20 weeks, thereby offering results earlier in the pregnancy. This brochure is to provide you with some basic information on CVS. A separate brochure is avail- able which describes amniocentesis. Who should consider CVS? CVS should be considered by women age 35 or older at the time of delivery, individuals who have had a child with a chromosome abnormality, individuals who have a chromosome translocation, and couples at risk for a prenatally diagnosable genetic disease (e.g., hemophilia or sickle cell disease). CVS is not appropriate for individuals with a family history of neural tube defects (spina bifida or anencephaly). When is CVS performed? CVS is traditionally performed between 10 - 13 weeks after a woman’s last menstrual period (during the first trimester). How is CVS performed? There are two methods for obtaining chorionic villi. For many women, either method can be safely per- formed. First, an ultrasound evaluation is performed to locate the developing placenta and to date the pregnancy. Often, the placental location determines which method of CVS is more appropriate. There are certain other obstetrical considerations which may make one method preferable, including uterine anatomy and vaginal infections. TRANSCERVICAL CVS: A thin catheter (hollow tube) is inserted into the vagina and through the cervix. -
Prenatal and Preimplantation Genetic Diagnosis for Mps and Related Diseases
PRENATAL AND PREIMPLANTATION GENETIC DIAGNOSIS FOR MPS AND RELATED DISEASES Donna Bernstein, MS Amy Fisher, MS Joyce Fox, MD Families who are concerned about passing on genetic conditions to their children have several options. Two of those options are using prenatal diagnosis and preimplantation genetic diagnosis. Prenatal diagnosis is a method of testing a pregnancy to learn if it is affected with a genetic condition. Preimplantation genetic diagnosis, also called PGD, is a newer technology used to test a fertilized embryo before a pregnancy is established, utilizing in vitro fertilization (IVF). Both methods provide additional reproductive options to parents who are concerned about having a child with a genetic condition. There are two types of prenatal diagnosis; one is called amniocentesis, and the other is called CVS (chorionic villus sampling). Amniocentesis is usually performed between the fifteenth and eighteenth weeks of pregnancy. Amniocentesis involves inserting a fine needle into the uterus through the mother's abdomen and extracting a few tablespoons of amniotic fluid. Skin cells from the fetus are found in the amniotic fluid. These cells contain DNA, which can be tested to see if the fetus carries the same alterations in the genes (called mutations) that cause a genetic condition in an affected family member. If the specific mutation in the affected individual is unknown, it is possible to test the enzyme activity in the cells of the fetus. Although these methods are effective at determining whether a pregnancy is affected or not, they do not generally give information regarding the severity or the course of the condition. -
L&D – Amnioinfusion Guideline and Procedure for Amnioinfusion
L&D – Amnioinfusion Guideline and Procedure for Amnioinfusion. Purpose: Replacing the amniotic fluid with normal saline has been found to be a safe, simple, and very effective way to reduce the occurrence of repetitive variable decelerations. Procedure: Initiation of Amnioinfusion will be ordered and performed by a Certified Nurse Midwife (CNM) or physician (MD). 1. Prepare NS or LR 1000ml with IV tubing in the same fashion as for intravenous infusion. Flush the tubing to clear air. 2. An intrauterine pressure catheter (IUPC) will be placed by the MD/CNM. 3. Elevate the IV bag 3-4 feet above the IUPC tip for rapid infusion. Infuse 250-500ml of solution over a 20-30 minute time frame followed by a 60-180ml/hour maintenance infusion. The total volume infused should not exceed 1000ml unless one has access to ultrasound and can titrate to an amniotic fluid index (AFI) of 8-12 cm to prevent polyhydramnios and hypertonus. 4. If variable decelerations recur or other new non-reassuring FHR patterns develop, notify the MD/CNM. The procedure may be repeated as ordered. 5. Resting tone of the uterus will be increased during infusion but should not increase > 15mmHg from previous baseline. If this occurs, infusion should stop until there is a return to the previous baseline then it can be restarted. An elevated baseline prior to infusion is a contraindication. 6. Monitor for an outflow of infusion. If there is a sudden cessation of outflow fetal head engagement may have occurred increasing the risk of polyhydramnios. Complications are rare but can include iatrogenic polyhydramnios, uterine hypertonus, chorioamnionitis, uterine rupture, placental abruption, and maternal pulmonary embolus. -
Prenatal Screening Tests: Options for Women 35 Or Older
Women who will be 35 or older on their due date are at higher risk for a group of birth defects called chromosome disorders. A screening test can give you more information about your chance to have a Prenatal Screening Tests baby with this type of birth defect. If you want a Options for women screening test during pregnancy, you can decide 35 or older which one seems right for you. How risk There are two main screening tests that look for birth defects: "State changes with age screening" and "NIPT". Either test can indicate if your pregnancy has a high or low chance for the baby to have a common chromosome disorder. Most Chance for Down syndrome pregnancies with Down syndrome and trisomy 18 can be found by starting with a screening test; however, screening tests occasionally miss these 25 year old 1 in 1250 30 year old 1 in 900 conditions. 35 year old 1 in 365 For women who will be 35 or older: 40 year old 1 in 100 • State screening detects 91-94% of babies with Down syndrome and trisomy 18 45 year old 1 in 30 • NIPT detects 98-99% of babies with Down syndrome and trisomy 18 State Screening NIPT State Screening is a more general test for birth NIPT is a more targeted screening test that looks for defects. This test estimates the risk for Down common chromosome disorders. This test estimates syndrome and trisomy 18, and can help find the risk for Down syndrome, trisomy 18, trisomy 13 pregnancies with certain physical birth defects. -
Proteomic Biomarkers of Intra-Amniotic Inflammation
0031-3998/07/6103-0318 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. Proteomic Biomarkers of Intra-amniotic Inflammation: Relationship with Funisitis and Early-onset Sepsis in the Premature Neonate CATALIN S. BUHIMSCHI, IRINA A. BUHIMSCHI, SONYA ABDEL-RAZEQ, VICTOR A. ROSENBERG, STEPHEN F. THUNG, GUOMAO ZHAO, ERICA WANG, AND VINEET BHANDARI Department of Obstetrics, Gynecology and Reproductive Sciences [C.S.B., I.A.B., S.A.-R., V.A.R., S.F.T., G.Z., E.W.], and Department of Pediatrics [V.B.], Division of Perinatal Medicine, Yale University School of Medicine, New Haven, CT 06520 ABSTRACT: Our goal was to determine the relationship between 4 vein inflammatory cytokine levels, but not maternal serum val- amniotic fluid (AF) proteomic biomarkers (human neutrophil de- ues, correlate with the presence and severity of the placental fensins 2 and 1, calgranulins C and A) characteristic of intra-amniotic histologic inflammation and umbilical cord vasculitis (7). inflammation, and funisitis and early-onset sepsis in premature neo- Funisitis is characterized by perivascular infiltrates of in- nates. The mass restricted (MR) score was generated from AF flammatory cells and is considered one of the strongest hall- obtained from women in preterm labor (n ϭ 123). The MR score marks of microbial invasion of the amniotic cavity and fetal ranged from 0–4 (none to all biomarkers present). Funisitis was graded histologically and interpreted in relation to the MR scores. inflammatory syndrome (8,9). While there is some debate with Neonates (n ϭ 97) were evaluated for early-onset sepsis. -
Amniotic Fluid Volume: When and How to Take Action
Amniotic fluid volume: When and how to take action http://contemporaryobgyn.modernmedicine.com/pr... Published on Contemporary OB/GYN (http://contemporaryobgyn.modernmedicine.com) Amniotic fluid volume: When and how to take action Alessandro Ghidini, MD and Marta Schilirò, MD and Anna Locatelli, MD Publish Date: JUN 01,2014 Dr. Ghidini is Professor, Georgetown University, Washington, DC, and Director, Perinatal Diagnostic Center, Inova Alexandria Hospital, Alexandria, Virginia. Dr. Schilirò is Medical Doctor, Obstetrics and Gynecology, University of Milano-Bicocca, Monza, Italy. Dr. Locatelli is Associate Professor, University of Milano-Bicocca, Monza, Italy, and Director, Department of Obstetrics and Gynecology, Carate- Giussano Hospital, AO Vimercate-Desio, Italy. None of the authors has a conflict of interest to report with respect to the content of this article. Assessment of amniotic fluid volume (AFV) is an integral part of antenatal ultrasound evaluation during screening exams, targeted anatomy examinations, and in tests assessing fetal well-being. 1 di 17 18/06/2014 11:10 Amniotic fluid volume: When and how to take action http://contemporaryobgyn.modernmedicine.com/pr... Abnormal AFV has been associated with an increased risk of perinatal mortality and several adverse perinatal outcomes, including premature rupture of membranes (PROM), fetal abnormalities, abnormal birth weight, and increased risk of obstetric interventions.1 A recent systematic review demonstrated associations between oligohydramnios, birthweight <10th percentile, and perinatal mortality, as well as between polyhydramnios, birthweight >90th percentile, and perinatal mortality. The predictive ability of AFV alone, however, was generally poor.2 How to assess AFV Ultrasound (U/S) examination is the only practical method of assessing AFV. -
Fetal Assement Methods
12/3/2020 Fetal Assement Methods 1 up to 9% of exam 5 to 9 questions 13.00 Adjunct Fetal Surveillance Methods 10%) 13.01 Auscultation (Intermittent Auscultation- IA) 13.02 Fetal movement counting 13.03 Nonstress testing 13.04 Fetal acid base interpretation – will be covered in a separate section 13.05 Biophysical profile 13.06 Fetal Acoustic Stimulation 2 1 12/3/2020 HERE IS ONE FOR YOU!! AWW… Skin to Skin in the OR ☺ 3 Auscultation 4 2 12/3/2020 Benefits of Auscultation • Based on Random Control Trials, neonatal outcomes are comparable to those monitored with EFM • Lower CS rates • Technique is non-invasive • Widespread application is possible • Freedom of movement • Lower cost • Hands on Time and one to one support are facilitated 5 Limitation of Auscultation • Use of the Fetoscope may limit the ability to hear FHR ( obesity, amniotic fluid, pt. movement and uterine contractions) • Certain FHR patterns cannot be detected – variability and some decelerations • Some women may think IA is intrusive • Documentation is not automatic • Potential to increase staff for 1:1 monitoring • Education, practice and skill assessment of staff 6 3 12/3/2020 Auscultation • Non-electronic devices such as a Fetoscope or Stethoscope • No longer common practice in the United States though may be increasing due to patient demand • Allows listening to sounds associated with the opening and closing of ventricular valves via bone conduction • Can hear actual heart sounds 7 Auscultation Fetoscope • A Fetoscope can detect: • FHR baseline • FHR Rhythm • Detect accelerations and decelerations from the baseline • Verify an FHR irregular rhythm • Can clarify double or half counting of EFM • AWHONN, (2015), pp. -
ENT of UATION MEMOR the HUMAN FETUS Cothelijne Van Heter
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/146798 Please be advised that this information was generated on 2021-09-24 and may be subject to change. ENT OF UATION MEMOR THE HUMAN FETUS Cothelijne van Heter • DEVELOPMENT OF HABITUATION AND MEMORY IN THE HUMAN FETUS Van Heteren, Cathelijne Francisca - Development of habituation and memory in the human fetus - 2001 Thesis University Nijmegen - with réf.- with summary m Dutch -136 p. ISBN: 90-9015000-5 Print: Grafisch Bedrijf Ponsen &i Looijen BV Wageningen Graphic Design Marie-Louise Dusée No part of this book may be reproduced in any form without permission of the author. This research project was financially supported by ZorgOnderzoek Nederland and the Hersenstichting Nederland. Publication of this thesis was financially supported by ATL Nederland BV, Ferring BV, GlaxoSmithKline, Hitachi Ultrasound BV, Medical Dynamics, Novo Nordisk Farma BV, Organon Nederland BV, Pie Medical Benelux BV, Sanofi-Synthélabo, Schering Nederland BV. DEVELOPMENT OF HABITUATION AND MEMORY IN THE HUMAN ?-f τ'••<, Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen Proefschrift ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen, volgens besluit van het College van Decanen in het openbaar te verdedigen op vrijdag 5 oktober 2001 des namiddags om 1.30 uur precies door Cathelijne Francisca van Heteren -
Cutoff Point Amniotic Fluid Index and Pregnancy Prognosis in the Third Trimester of Pregnancy in Shariati Hospital of Bandar Abbas in 2013-14
Available online at www.ijmrhs.com International Journal of Medical Research & ISSN No: 2319-5886 Health Sciences, 2016, 5, 12:212-216 Cutoff point amniotic fluid index and pregnancy prognosis in the third trimester of pregnancy in Shariati Hospital of Bandar Abbas in 2013-14 AzinAlavi 1, Najmesadat Mosallanezhad 1,Hosein Hamadiyan 2, Mohammad Amin Sepehri Oskooe 2 and Keivan Dolati 2* 1Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran 2Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran *CorrespondingEmail:[email protected] _____________________________________________________________________________________________ ABSTRACT Background and purpose of study: Amniotic fluid volume varies according to different stages of fetal growth and its different requirements. Disrupted amniotic fluid volume is associated with an increased risk for the fetus. The present research aims to investigate the effect of cutoff point amniotic fluid index on pregnancy prognosis at the third trimester of pregnancy in Shariati hospital of Bandar Abbas. Materials and methods: In the present analytical, cross-sectional research, AFI ≤ 5 cm was considered as oligohydramnios; AFI 5.1-8 was taken as the cut-off point; AFI ˃ 8.1-24 was regarded as normal; AFI ˃ 24 was considered as polyhydramnios. The data were analyzed via SPSS version 16.0 using Chi-squared test, Fisher’s test, Mann-Whitney U-test and Spearman’s correlation coefficient. P-value was set at ≤ .05 for the significance of data. Findings: Subjects with cut-off point AFI (5.1-8) were 38 (40.4%); those with normal AFI (8.1-24) were 56 (59.6%). The mean score of AFI was 8.85±9.54cm. -
The Empire Plan SEPTEMBER 2018 REPORTING ON
The Empire Plan SEPTEMBER 2018 REPORTING ON PRENATAL CARE Every baby deserves a healthy beginning and you can take steps before your baby is even born to help ensure a great start for your infant. That’s why The Empire Plan offers mother and baby the coverage you need. When your primary coverage is The Empire Plan, the Empire Plan Future Moms Program provides you with special services. For Empire Plan enrollees and for their enrolled dependents, COBRA enrollees with their Empire Plan benefits and Young Adult Option enrollees TABLE OF CONTENTS Five Important Steps ........................................ 2 Feeding Your Baby ...........................................11 Take Action to Be Healthy; Breastfeeding and Your Early Pregnancy ................................................. 4 Empire Plan Benefits .......................................12 Prenatal Testing ................................................. 5 Choosing Your Baby’s Doctor; New Parents ......................................................13 Future Moms Program ......................................7 Extended Care: Medical Case High Risk Pregnancy Program; Management; Questions & Answers ...........14 Exercise During Pregnancy ............................ 8 Postpartum Depression .................................. 17 Your Healthy Diet During Pregnancy; Medications and Pregnancy ........................... 9 Health Care Spending Account ....................19 Skincare Products to Avoid; Resources ..........................................................20 Childbirth Education